181 related articles for article (PubMed ID: 15199655)
21. Switching to amisulpride monotherapy for treatment-resistant schizophrenia.
Kontaxakis VP; Havaki-Kontaxaki BJ; Ferentinos PP; Paplos KG; Soldatos CR
Eur Psychiatry; 2006 Apr; 21(3):214-7. PubMed ID: 16531015
[TBL] [Abstract][Full Text] [Related]
22. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
Kasper S
Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
[TBL] [Abstract][Full Text] [Related]
23. Treatment of negative symptoms in schizophrenia with amisulpride.
Boyer P; Lecrubier Y; Puech AJ; Dewailly J; Aubin F
Br J Psychiatry; 1995 Jan; 166(1):68-72. PubMed ID: 7894879
[TBL] [Abstract][Full Text] [Related]
24. Treatment of positive and negative symptoms: pharmacologic approaches.
Boyer P; Lecrubier Y; Puech AJ
Mod Probl Pharmacopsychiatry; 1990; 24():152-74. PubMed ID: 1970852
[No Abstract] [Full Text] [Related]
25. Focus on amisulpride.
Green B
Curr Med Res Opin; 2002; 18(3):113-7. PubMed ID: 12094819
[TBL] [Abstract][Full Text] [Related]
26. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
Blin O
Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Colonna L; Saleem P; Dondey-Nouvel L; Rein W
Int Clin Psychopharmacol; 2000 Jan; 15(1):13-22. PubMed ID: 10836281
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
[TBL] [Abstract][Full Text] [Related]
29. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
[TBL] [Abstract][Full Text] [Related]
30. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Hwang TJ; Lee SM; Sun HJ; Lin HN; Tsai SJ; Lee YC; Chen YS
J Formos Med Assoc; 2003 Jan; 102(1):30-6. PubMed ID: 12684609
[TBL] [Abstract][Full Text] [Related]
31. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
[TBL] [Abstract][Full Text] [Related]
32. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.
Speller JC; Barnes TR; Curson DA; Pantelis C; Alberts JL
Br J Psychiatry; 1997 Dec; 171():564-8. PubMed ID: 9519098
[TBL] [Abstract][Full Text] [Related]
33. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride.
Saleem P; Olié JP; Loo H
Int Clin Psychopharmacol; 2002 Jan; 17(1):1-8. PubMed ID: 11806403
[TBL] [Abstract][Full Text] [Related]
34. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
Hofer A; Rettenbacher MA; Edlinger M; Huber R; Bodner T; Kemmler G; Sachs G; Fleischhacker WW
Pharmacopsychiatry; 2007 Jan; 40(1):1-8. PubMed ID: 17327953
[TBL] [Abstract][Full Text] [Related]
35. THE LESSA (Lebanese Short-term Study with Amisulpride) STUDY a Phase IV clinical trial in acutely ill schizophrenic patients.
Baddoura R; Ourgandjian H
J Med Liban; 2004; 52(2):78-85. PubMed ID: 15884686
[TBL] [Abstract][Full Text] [Related]
36. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
37. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
Kim SW; Shin IS; Kim JM; Yang SJ; Hwang MY; Yoon JS
J Clin Psychopharmacol; 2008 Jun; 28(3):349-52. PubMed ID: 18480697
[No Abstract] [Full Text] [Related]
38. Safety of amisulpride (Solian): a review of 11 clinical studies.
Coulouvrat C; Dondey-Nouvel L
Int Clin Psychopharmacol; 1999 Jul; 14(4):209-18. PubMed ID: 10468313
[TBL] [Abstract][Full Text] [Related]
39. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
Zink M; Knopf U; Henn FA; Thome J
Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
[TBL] [Abstract][Full Text] [Related]
40. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Lecrubier Y; Quintin P; Bouhassira M; Perrin E; Lancrenon S
Acta Psychiatr Scand; 2006 Nov; 114(5):319-27. PubMed ID: 17022791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
